Follow RSS for latest reports on this topicAubagio (Teriflunomide) - Market Research and Reports
AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS).
The Science Behind AUBAGIO
The proposed mechanism of action of AUBAGIO is based on preclinical laboratory and animal model data.1 The exact mechanism by which AUBAGIO exerts its therapeutic effect in multiple sclerosis (MS) is not fully understood.2
Research supports that AUBAGIO inhibits the proliferation of stimulated T and B lymphocytes in the periphery, limiting overactivation of immune responses that can contribute to MS disease activity1-3
- AUBAGIO has been demonstrated to selectively and reversibly inhibit dihydroorotate dehydrogenase (DHODH) required by rapidly dividing cells1-4
- Results from preclinical laboratory and animal model studies suggest that by blocking the de novo pyrimidine synthesis pathway, AUBAGIO exerts a cytostatic effect on stimulated proliferating T and B cells in the periphery1,2,5
- Through this effect, AUBAGIO is thought to target cellular functions associated with overreactive immune responses and, therefore, has the potential to reduce the number of activated T and B cells available to migrate into the central nervous system (CNS)1,2,4
- Since the pyrimidine salvage pathway is unaffected by AUBAGIO, basic homeostatic cell functions of resting and slowly-dividing lymphocytes appear to be preserved1,2,5
1 - Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011;124(2):75-84.
2 -Kieseier B, Kaplan J, Wiendl H. A proposed mechanism of action for teriflunomide in multiple sclerosis. Presented at European Charcot Foundation Symposium, 2012.
3 - Cherwinski HM, McCarley D, Schatzman R, Devens B, Ransom JT. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther. 1995;272:460-468.
4 - AUBAGIO (teriflunomide) [package insert]. Cambridge, MA: Genzyme Corporation; September 2012.
5 - Rückemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem. 1998;273:21682-21691.
For further information open - https://www.aubagio.com/
BioPortfolio's Easy Ordering System
- Search for the report you need from our store
- Make online payment with our easy checkout process
- Receive PDF report via email
Easy Online Payment or Pro Forma Invoice
We accept the following credit cards...
or can supply a pro-forma invoice if required.
We found 1 reports that matched your search.
Refine your search, and find more matches, using the form above.
FirstImpact: FDA approval of Aubagio
IntroductionReport OverviewFollowing US approval of Aubagio (teriflunomide; Sanofi/Genzyme) for use in Relapsing Remitting Multiple Sclerosis patients (RRMS), FirstWord interviewed nearly 300 US-based neurologists within 24 hours of the announcement. Based on this poll, this FirstImpact report identifies prescribing intentions and attitudes of practicing physicians to measure the impact of Aubagio...Read More >>>
Published by: FirstWord Pharma
Prices Starting From: